L. Rorick‐Kehn

发表

Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.

R. Mohs, A. Post, R. Anton, 2016, Alcoholism, clinical and experimental research.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, S. Mitchell, G. Gilmour, 2017, The Journal of Pharmacology and Experimental Therapeutics.

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

G. Marek, K. Perry, J. Witkin, 2011, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

G. Marek, E. Nisenbaum, D. McKinzie, 2007, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and Pharmacokinetic Properties of a Structurally-Novel , Potent , Selective mGlu 2 / 3 Receptor Agonist : In Vitro Characterization of LY 404039

G. Marek, E. Nisenbaum, D. McKinzie, 2007 .

Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

S. Tauscher‐Wisniewski, L. Rorick-Kehn, G. Dickinson, 2014, Journal of clinical pharmacology.

NOP receptor antagonists decrease alcohol drinking in the dark in C57BL/6J mice.

J. Pintar, R. Ciccocioppo, Gloria Brunori, 2019, Alcoholism, clinical and experimental research.

Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction

F. Weiss, R. Ciccocioppo, M. Statnick, 2017, Neuropsychopharmacology.

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models

H. Becker, L. Rorick-Kehn, Rachel I Anderson, 2014, Front. Neurosci..

Melanin-Concentrating Hormone-1 Receptor Modulates Neuroendocrine, Behavioral, and Corticolimbic Neurochemical Stress Responses in Mice

D. McKinzie, G. Nomikos, J. Witkin, 2006, Neuropsychopharmacology.

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

S. Mitchell, J. Witkin, D. Schoepp, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists for the Treatment of Depression

V. Tolstikov, S. Mitchell, G. Gilmour, 2017 .

The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

J. Pintar, M. Ansonoff, J. Witkin, 2014, Pharmacology & therapeutics.

Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

B. Cohen, W. Carlezon, C. Chavkin, 2011, Molecular Pharmacology.

Amygdalar unit activity during three learning tasks: eyeblink classical conditioning, Pavlovian fear conditioning, and signaled avoidance conditioning.

J. Steinmetz, L. Rorick-Kehn, L. Rorick‐Kehn, 2005, Behavioral neuroscience.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

K. Perry, D. McKinzie, J. Witkin, 2007, Psychopharmacology.

Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands

D. McKinzie, L. Rorick-Kehn, J. Hart, 2005, Psychopharmacology.

The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype

D. McKinzie, C. Felder, L. Rorick-Kehn, 2013, Neuropsychopharmacology.

Ipsilesional versus contralesional postural deficits induced by unilateral brain trauma: a side reversal by opioid mechanism

J. Schouenborg, J. Kehr, N. Marklund, 2020, Brain communications.

Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human

J. Suico, D. McKinzie, J. McKinzie, 2015, The international journal of neuropsychopharmacology.

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

J. Pintar, M. Ansonoff, J. Witkin, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344

D. McKinzie, D. Schoepp, L. Rorick-Kehn, 2006, Journal of Pharmacology and Experimental Therapeutics.

NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area

F. Weiss, R. Narendran, R. Ciccocioppo, 2019, British journal of pharmacology.

A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

F. Weiss, K. Perry, J. Witkin, 2016, Alcoholism, clinical and experimental research.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy

T. Fitch, L. Rorick-Kehn, C. Jesudason, 2014, Front. Neurosci..

Preclinical findings predicting efficacy and side‐effect profile of LY2940094, an antagonist of nociceptin receptors

Janice W. Smith, D. McKinzie, J. Pintar, 2016, Pharmacology research & perspectives.